Literature DB >> 14522360

Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade.

Carmen Mazzola1, Vincenzo Micale, Filippo Drago.   

Abstract

Administration of drugs activating cannabinoid CB(1) receptors in the brain induces memory deficit in rodents, and blockade of these receptors may restore memory capacity in these animals. Central administration of beta-amyloid or beta-amyloid fragments may also lead to memory disturbances. This study was undertaken to study the involvement of cannabinoid CB(1) receptors in amnesia induced by beta-amyloid fragments in mice tested in a step-through passive avoidance paradigm. Pre-training intracerebroventricular (i.c.v.) injection of beta-amyloid fragments, beta-amyloid peptide-(25-35) (4, 8 or 16 nmol/mouse) or beta-amyloid peptide-(1-42) (200, 400, 800 pmol/mouse) 7 days prior to the learning trial reduced in a dose-dependent manner the retention of passive avoidance response. This effect was observed in two retention tests, 1 and 7 days after the learning trial. The two beta-amyloid fragments showed similar potency in reducing retention of passive avoidance behavior. This effect was counteracted by a single intraperitoneal (i.p.) injection of the cannabinoid CB(1) receptor antagonist, N-(piperidin-l-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A, 1 mg/kg), made 30 min prior to the second retention test. The injection of SR141716A per se did not affect memory capacity of mice. The i.c.v. administration of beta-amyloid peptide-(25-35) (8 nmol/mouse) or of beta-amyloid peptide-(1-42) (400 pmol/mouse) made 30 min prior to the learning trial failed to affect the retention capacity of mice as measured 1 and 7 days later. Also, the i.p. injection of SR 141716A (1 mg/kg) made 30 min prior to the learning trial did not influence the behavioral response of mice injected with beta-amyloid peptide-(25-35) (8 nmol/mouse) or of beta-amyloid peptide-(1-42) (400 pmol/mouse) 7 days prior to the learning trial. These results show that beta-amyloid fragments induce a dose-dependent memory deficit. Their effect on memory retention depends upon the time of administration and seems to involve cannabinoid CB(1) receptors in the brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522360     DOI: 10.1016/j.ejphar.2003.08.026

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  29 in total

1.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

2.  The endocannabinoid system and Alzheimer's disease.

Authors:  Cristina Benito; Estefanía Núñez; María Ruth Pazos; Rosa María Tolón; Julián Romero
Journal:  Mol Neurobiol       Date:  2007-09-05       Impact factor: 5.590

3.  Differential endocannabinoid regulation of extinction in appetitive and aversive Barnes maze tasks.

Authors:  John P Harloe; Andrew J Thorpe; Aron H Lichtman
Journal:  Learn Mem       Date:  2008-10-28       Impact factor: 2.460

Review 4.  Targeting the endocannabinoid system in Alzheimer's disease.

Authors:  Jeremy Koppel; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

5.  Scutellarin protects against Aβ-induced learning and memory deficits in rats: involvement of nicotinic acetylcholine receptors and cholinesterase.

Authors:  Li-li Guo; Zhi-zhong Guan; Yong-lin Wang
Journal:  Acta Pharmacol Sin       Date:  2011-10-10       Impact factor: 6.150

6.  Pharmacological elevation of anandamide impairs short-term memory by altering the neurophysiology in the hippocampus.

Authors:  Anushka V Goonawardena; John Sesay; Cheryl Ann Sexton; Gernot Riedel; Robert E Hampson
Journal:  Neuropharmacology       Date:  2011-07-13       Impact factor: 5.250

Review 7.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 8.  Endocannabinoid signalling and the deteriorating brain.

Authors:  Vincenzo Di Marzo; Nephi Stella; Andreas Zimmer
Journal:  Nat Rev Neurosci       Date:  2015-01       Impact factor: 34.870

Review 9.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

10.  Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors.

Authors:  Carmen Mazzola; Julie Medalie; Maria Scherma; Leigh V Panlilio; Marcello Solinas; Gianluigi Tanda; Filippo Drago; Jean Lud Cadet; Steven R Goldberg; Sevil Yasar
Journal:  Learn Mem       Date:  2009-04-29       Impact factor: 2.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.